Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

argenex (ARGX) Stock Forecast & Price Target

argenex logo
$873.71 -2.05 (-0.23%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$871.02 -2.70 (-0.31%)
As of 10/23/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenex - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
6
Buy
24

Based on 30 Wall Street analysts who have issued ratings for argenex in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 6 have given a hold rating, 23 have given a buy rating, and 1 has given a strong buy rating for ARGX.

Consensus Price Target

$1,142.37
30.75% Upside
According to the 30 analysts' twelve-month price targets for argenex, the average price target is $1,142.37. The highest price target for ARGX is $1,400.00, while the lowest price target for ARGX is $861.00. The average price target represents a forecasted upside of 30.75% from the current price of $873.71.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenex and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARGX Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
1 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
23 Buy rating(s)
21 Buy rating(s)
20 Buy rating(s)
19 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$1,142.37$1,165.11$1,062.79$817.53
Forecasted Upside30.75% Upside21.43% Upside19.57% Upside0.03% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenex Stock vs. The Competition

TypeargenexHealthcare CompaniesBroader Market
Consensus Rating Score
2.83
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside30.75% Upside1,400.11% Upside16.92% Upside
News Sentiment Rating
Neutral News

See Recent ARGX News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
Sean Laaman
5 of 5 stars
Boost TargetOverweight$1,140.00 ➝ $1,190.00+35.64%
10/23/2026
Guggenheim logo
Guggenheim
5 of 5 stars
Yatin Suneja
5 of 5 stars
Lower TargetBuy$1,185.00 ➝ $1,120.00+28.66%
10/23/2026
Derek Archila
Derek Archila
5 of 5 stars
Lower TargetOverweight$1,356.00 ➝ $1,336.00+53.86%
10/23/2026Boost TargetNeutral$823.00 ➝ $861.00-1.69%
10/21/2026 Reiterated RatingHold (C)
10/20/2026Lower TargetOutperform$1,100.00 ➝ $1,025.00+19.29%
10/12/2026Lower TargetOutperform$1,100.00 ➝ $1,038.00+26.81%
10/9/2026 Reiterated RatingNeutral
10/9/2026 Reiterated RatingBuy
10/8/2026Lower TargetOutperform$1,150.00 ➝ $1,130.00+38.10%
10/8/2026 Reiterated RatingBuy
9/25/2026 Reiterated RatingBuy
9/14/2026 Reiterated RatingBuy
9/7/2026 Reiterated RatingBuy
8/26/2026UpgradeNeutral ➝ Buy$960.00 ➝ $1,400.00+37.32%
8/18/2026Boost TargetBuy$1,030.00 ➝ $1,095.00+8.89%
8/18/2026Boost TargetMarket Outperform$932.00 ➝ $1,200.00+21.48%
8/18/2026Boost TargetBuy$940.00 ➝ $1,202.00+21.68%
8/17/2026Boost TargetOverweight$1,075.00 ➝ $1,215.00+22.35%
8/5/2026 Reiterated RatingBuy
7/21/2026Boost TargetBuy$1,152.00 ➝ $1,182.00+35.70%
7/2/2026Boost TargetBuy$1,016.00 ➝ $1,088.00+14.60%
6/22/2026 Initiated CoverageOutperform$1,219.00+49.01%
6/3/2026 Reiterated RatingBuy
4/3/2026 UpgradeStrong-Buy
2/20/2026 UpgradeStrong Sell ➝ Hold
12/11/2025Boost TargetBuy$1,028.00 ➝ $1,248.00+40.21%
11/24/2025Reiterated RatingOutperform ➝ Peer Perform
10/31/2025Boost TargetBuy$800.00 ➝ $1,146.00+41.49%
10/31/2025Boost TargetOutperform$775.00 ➝ $910.00+10.93%
2/28/2025Reiterated RatingOutperform
11/5/2024UpgradeSector Perform ➝ Sector Outperform$439.00 ➝ $715.00+21.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:39 PM ET.


Should I Buy argenex Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 21, 2026. Please send any questions or comments about these argenex pros and cons to contact@marketbeat.com.

argenex
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in argenx SE:

  • argenx SE recently reported strong third-quarter financial results, posting earnings per share of $7.32, which significantly exceeded the analyst consensus estimate of $5.86, demonstrating robust profitability and operational efficiency that supports the current stock price of $890.05.
  • The company's lead product, VYVGART, continues to drive substantial revenue growth, with the most recent quarter generating $1.54 billion in revenue compared to the expected $1.45 billion, highlighting the strong market demand for its therapies targeting severe autoimmune diseases like generalized myasthenia gravis.
  • Wall Street maintains a positive outlook on the stock, with a consensus rating of "Moderate Buy" and a consensus price target of $1,158.61, suggesting significant potential upside from the current trading levels as analysts like Wells Fargo and BNP Paribas Exane have recently issued "overweight" and "outperform" ratings.
  • Institutional investor confidence is rising, evidenced by significant position increases in the third quarter, such as Assenagon Asset Management S.A. growing its holdings by 120.3% and Gunderson Capital Management LLC establishing a new stake worth approximately $5.8 million, indicating strong professional interest in the company's long-term trajectory.
  • argenx SE is expanding its clinical pipeline with promising developments, including the presentation of Phase 3 ALKIVIA results in autoimmune myositis at the ACR Convergence 2026 conference, which positions the company to capture additional market share in the immunology sector beyond its current approved indications.

argenex
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in argenx SE for these reasons:

  • Several major financial institutions have recently lowered their price targets, with Royal Bank Of Canada cutting its target from $1,100.00 to $1,025.00 and Oppenheimer reducing its target from $1,100.00 to $1,038.00, suggesting that some analysts believe the stock may be overvalued relative to its current growth rate.
  • The stock has experienced significant volatility and recent price declines, including a gap down of approximately $97.21 on October 8, 2026, and trading well below its 52-week high of $1,072.75, which may indicate short-term market uncertainty or profit-taking by investors.
  • Legal risks remain a concern for shareholders, as indicated by recent reports of a fraud investigation involving argenx SE, where investors with significant losses are being encouraged to join a class action lawsuit, which could lead to potential financial liabilities and reputational damage for the company.
  • Despite strong earnings, the company faces a high valuation with a price-to-earnings ratio of 33.40, which may limit further upside potential if future earnings growth does not accelerate to justify the premium price, particularly as the stock trades above its 200-day moving average of $882.64.
  • Short interest in the stock has remained relatively stable at approximately 2.2% of the float, with days to cover around 4.94, indicating that a portion of the market remains skeptical about the stock's direction and is positioned to profit from potential price declines.

ARGX Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for argenex is $1,142.37, with a high forecast of $1,400.00 and a low forecast of $861.00.

30 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenex in the last twelve months. There are currently 6 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.

According to analysts, argenex's stock has a predicted upside of 30.75% based on their 12-month stock forecasts.

Over the previous 90 days, argenex's stock had 1 upgrade and 1 downgrade by analysts.

Analysts like argenex more than other "healthcare" companies. The consensus rating for argenex is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ARGX compares to other companies.


MarketBeat monitors more than a dozen sources for argenex analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners